![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Sooma Receives Breakthrough Status for At-Home Depression Treatment Device
Sooma Receives Breakthrough Status for At-Home Depression Treatment Device
Finland-based Sooma Medical has been granted FDA Breakthrough Device status for its portable at-home neuromodulation device to treat depression.
The device uses a non-invasive mild electrical current to stimulate targeted brain areas to improve depressive symptoms.
The treatment, which can be stand-alone or used in combination with drug therapy, consists of daily 30-minute sessions for a minimum of three weeks.
Most patients see results around the third week of treatment, the company said. According to Sooma's post-market data, more than half of patients achieve a complete clinical response in their depressive symptoms after the treatment.
The FDA's breakthrough designation is for novel therapies that show significant potential to provide a substantial improvement over existing options for severe or life-threatening conditions.
Upcoming Events
-
18Jul
-
21Oct